CA3213222A1 - Identification of clonal neoantigens and uses thereof - Google Patents
Identification of clonal neoantigens and uses thereof Download PDFInfo
- Publication number
- CA3213222A1 CA3213222A1 CA3213222A CA3213222A CA3213222A1 CA 3213222 A1 CA3213222 A1 CA 3213222A1 CA 3213222 A CA3213222 A CA 3213222A CA 3213222 A CA3213222 A CA 3213222A CA 3213222 A1 CA3213222 A1 CA 3213222A1
- Authority
- CA
- Canada
- Prior art keywords
- tumour
- clonal
- mutation
- sample
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B30/10—Sequence alignment; Homology search
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medical Informatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Evolutionary Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Theoretical Computer Science (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- Primary Health Care (AREA)
- Molecular Biology (AREA)
- Data Mining & Analysis (AREA)
- Mycology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2104715.4 | 2021-04-01 | ||
| GBGB2104715.4A GB202104715D0 (en) | 2021-04-01 | 2021-04-01 | Identification of clonal neoantigens and uses thereof |
| PCT/EP2022/058793 WO2022207925A1 (en) | 2021-04-01 | 2022-04-01 | Identification of clonal neoantigens and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3213222A1 true CA3213222A1 (en) | 2022-10-06 |
Family
ID=75883641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3213222A Pending CA3213222A1 (en) | 2021-04-01 | 2022-04-01 | Identification of clonal neoantigens and uses thereof |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11504398B2 (https=) |
| EP (1) | EP4313125A1 (https=) |
| JP (1) | JP2024513781A (https=) |
| KR (1) | KR20230165259A (https=) |
| CN (1) | CN117120080A (https=) |
| AU (1) | AU2022251011A1 (https=) |
| CA (1) | CA3213222A1 (https=) |
| GB (1) | GB202104715D0 (https=) |
| IL (1) | IL306136A (https=) |
| WO (1) | WO2022207925A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202104715D0 (en) | 2021-04-01 | 2021-05-19 | Achilles Therapeutics Uk Ltd | Identification of clonal neoantigens and uses thereof |
| GB202202880D0 (en) | 2022-03-02 | 2022-04-13 | Achilles Therapeutics Uk Ltd | Methods for peptide synthesis |
| GB202205147D0 (en) | 2022-04-07 | 2022-05-25 | Achilles Therapeutics Uk Ltd | Identification of clonal neoantigens and uses thereof |
| WO2024194208A1 (en) | 2023-03-17 | 2024-09-26 | Achilles Therapeutics Uk Limited | Prediction of immunogenicity |
| GB202307096D0 (en) | 2023-05-12 | 2023-06-28 | Achilles Therapeutics Uk Ltd | Method |
| WO2024256485A1 (en) | 2023-06-15 | 2024-12-19 | Achilles Therapeutics Uk Limited | Identification of neoantigen peptides |
| GB202407727D0 (en) | 2024-05-31 | 2024-07-17 | Ucl Business Ltd | Reporters constructs, systems and assays |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150197785A1 (en) | 2012-08-10 | 2015-07-16 | The Broad Institute, Inc. | Methods and apparatus for analyzing and quantifying dna alterations in cancer |
| EP2983702A2 (en) | 2013-04-07 | 2016-02-17 | The Broad Institute, Inc. | Compositions and methods for personalized neoplasia vaccines |
| WO2015085147A1 (en) * | 2013-12-05 | 2015-06-11 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
| US20160310584A1 (en) | 2013-12-06 | 2016-10-27 | The Broad Institute Inc. | Formulations for neoplasia vaccines |
| KR20230076867A (ko) | 2013-12-20 | 2023-05-31 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신생항원 백신과의 병용 요법 |
| CN117467603A (zh) | 2015-04-27 | 2024-01-30 | 癌症研究技术有限公司 | 治疗癌症的方法 |
| TW202241500A (zh) | 2015-06-09 | 2022-11-01 | 美商博德研究所有限公司 | 用於贅瘤疫苗之調配物及其製備方法 |
| GB201516047D0 (en) * | 2015-09-10 | 2015-10-28 | Cancer Rec Tech Ltd | Method |
| ES2861477T3 (es) * | 2015-12-03 | 2021-10-06 | Ares Trading Sa | Método para determinar la clonalidad celular |
| WO2018136664A1 (en) * | 2017-01-18 | 2018-07-26 | Ichan School Of Medicine At Mount Sinai | Neoantigens and uses thereof for treating cancer |
| US12286678B2 (en) * | 2017-03-20 | 2025-04-29 | Ontario Institute For Cancer Research (Oicr) | Cancer risk based on tumour clonality |
| AU2018298971B2 (en) * | 2017-07-14 | 2025-01-23 | Cancer Research Technology Limited | Analysis of HLA alleles in tumours and the uses thereof |
| WO2019109086A1 (en) * | 2017-12-01 | 2019-06-06 | Illumina, Inc. | Methods and systems for determining somatic mutation clonality |
| IL259392A (en) * | 2018-05-15 | 2018-08-01 | Yeda Res & Dev | Vaccination with cancer neoantigens |
| US11189361B2 (en) * | 2018-06-28 | 2021-11-30 | International Business Machines Corporation | Functional analysis of time-series phylogenetic tumor evolution tree |
| CN111785322A (zh) * | 2019-12-30 | 2020-10-16 | 杭州慕谷基因科技有限公司 | 一种结肠腺癌基因组变异与肿瘤进化关系的研究方法 |
| GB202104715D0 (en) | 2021-04-01 | 2021-05-19 | Achilles Therapeutics Uk Ltd | Identification of clonal neoantigens and uses thereof |
| GB202205147D0 (en) * | 2022-04-07 | 2022-05-25 | Achilles Therapeutics Uk Ltd | Identification of clonal neoantigens and uses thereof |
-
2021
- 2021-04-01 GB GBGB2104715.4A patent/GB202104715D0/en not_active Ceased
-
2022
- 2022-04-01 AU AU2022251011A patent/AU2022251011A1/en active Pending
- 2022-04-01 CN CN202280026453.4A patent/CN117120080A/zh active Pending
- 2022-04-01 JP JP2023558897A patent/JP2024513781A/ja active Pending
- 2022-04-01 IL IL306136A patent/IL306136A/en unknown
- 2022-04-01 US US17/711,372 patent/US11504398B2/en active Active
- 2022-04-01 WO PCT/EP2022/058793 patent/WO2022207925A1/en not_active Ceased
- 2022-04-01 EP EP22720410.4A patent/EP4313125A1/en active Pending
- 2022-04-01 KR KR1020237035334A patent/KR20230165259A/ko active Pending
- 2022-04-01 CA CA3213222A patent/CA3213222A1/en active Pending
- 2022-10-11 US US17/963,665 patent/US12548651B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20230071113A1 (en) | 2023-03-09 |
| US11504398B2 (en) | 2022-11-22 |
| US20220323499A1 (en) | 2022-10-13 |
| JP2024513781A (ja) | 2024-03-27 |
| WO2022207925A1 (en) | 2022-10-06 |
| US12548651B2 (en) | 2026-02-10 |
| KR20230165259A (ko) | 2023-12-05 |
| CN117120080A (zh) | 2023-11-24 |
| GB202104715D0 (en) | 2021-05-19 |
| IL306136A (en) | 2023-11-01 |
| EP4313125A1 (en) | 2024-02-07 |
| AU2022251011A1 (en) | 2023-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11504398B2 (en) | Identification of clonal neoantigens and uses thereof | |
| Leader et al. | Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification | |
| Creelan et al. | Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial | |
| Budczies et al. | Tumour mutational burden: clinical utility, challenges and emerging improvements | |
| US12331359B2 (en) | Neoantigens and uses thereof for treating cancer | |
| Anagnostou et al. | Evolution of neoantigen landscape during immune checkpoint blockade in non–small cell lung cancer | |
| Zheng et al. | Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing | |
| Sanborn et al. | Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination | |
| Kiyotani et al. | Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma | |
| US20250218535A1 (en) | Identification of clonal neoantigens and uses thereof | |
| Liu et al. | Prediction of unfavourable response to checkpoint blockade in lung cancer patients through an integrated tumour-immune expression score | |
| Hao et al. | Dynamics of the Γδtcr repertoires during the dedifferentiation process and pilot implications for immunotherapy of thyroid cancer | |
| US20240412813A1 (en) | Methods and systems for tumour monitoring | |
| WO2024061628A1 (en) | Allele specific expression | |
| CA3268552A1 (en) | Allele specific expression | |
| Buttigieg et al. | Inflammatory reprogramming of the tumor microenvironment by infiltrating clonal hematopoiesis is associated with adverse outcomes in solid cancer | |
| WO2024256485A1 (en) | Identification of neoantigen peptides | |
| Ladd et al. | Uncovering Cellular Interactome Drivers of Immune Checkpoint Inhibitor Response in Advanced Melanoma Patients: S. Ladd et al. | |
| Moore et al. | A conserved subset of cold tumors responsive to immune checkpoint blockade | |
| Lee | Microenvironment-Mediated Immune Evasion in Primary Non-small Cell Lung Cancer | |
| Borden | Immune Recognition and Sculpting of Neoantigens in Human Tumors | |
| Barroux et al. | MEMORI-Methods for computational analyses | |
| Lin et al. | Neoantigens heterogeneity as a prognostic marker in patients with resected intrahepatic cholangiocarcinoma | |
| Moore et al. | Lack of TGFβ signaling competency predicts conversion of immune poor cancer to immune rich and response to checkpoint blockade. | |
| Nofech-Mozes | A Single-Cell Compendium of Intratumoural Heterogeneity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250328 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250328 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260331 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20260331 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260331 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260401 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260402 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260402 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260402 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260402 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260402 |